Kiora Pharmaceuticals Inc
KPRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.29
KIRA · Stoqly’s AI analyst, in plain words
- Kiora Pharmaceuticals Inc had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Kiora Pharmaceuticals Inc lost $10.8M in fiscal 2025.
- Free cash flow was −$10.1M in fiscal 2025, — of revenue.
Market cap
$14.1M
P/E
—
Revenue
$0.0M
Net income
−$10.8M
Free cash flow
−$10.1M
Operating margin
—
Kiora Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$10.8M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kiora Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- KIORA PHARMACEUTICALS INC
- CIK
- 0001372514
Kiora Pharmaceuticals Inc · KPRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | — | $0.0M | $16.0M | $0.0M |
| Revenue growth | −100.0% | — | — | — | −100.0% |
| Operating margin | — | — | — | 28.2% | — |
| Net income | −$13.8M | −$13.6M | −$12.5M | $3.6M | −$10.8M |
| Net margin | — | — | — | 22.4% | — |
| Diluted EPS | −$57.12 | −$18.55 | −$24.25 | $0.87 | −$2.64 |
| Cash | |||||
| Cash from operations | −$10.7M | −$10.4M | −$9.6M | $8.6M | −$10.0M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$10.7M | −$10.4M | −$9.6M | $8.6M | −$10.1M |
| FCF margin | — | — | — | 53.4% | — |
| Share count change | −94.7% | 203.7% | −26.5% | 666.7% | −0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $7.9M | $6.0M | $2.5M | $26.8M | $17.1M |
| Shareholders' equity | $14.6M | $11.4M | $6.1M | $25.8M | $16.1M |
| Current ratio | 5.6x | 2.3x | 2.9x | 4.9x | 6.0x |
| Interest coverage | −2,063.2x | −1,431.3x | −1,134.0x | 210.8x | −641.6x |
| Returns and quality | |||||
| Return on equity | −113.3% | −104.5% | −142.9% | 22.6% | −51.7% |
| Return on tangible equity | −361.4% | −2,044.5% | — | 18.8% | −77.0% |
| Piotroski F-score | 3 | — | — | 6 | 3 |
| Altman Z'' | −19.2 | −24.7 | −38.8 | −5.2 | −17.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kiora Pharmaceuticals Inc · KPRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.29 a share, the company is worth $14.1M.
Source: SEC EDGAR XBRL filings (CIK 0001372514). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.